Cambridge Pharmaceuticals Limited

REPORT AND FINANCIAL STATEMENTS

for the period ended 31 March 2005

LD5 *L3L0B7UA* 0338
COMPANIES HOUSE 04/08/05

Cambridge Pharmaceuticals Limited DIRECTORS AND OFFICERS

DIRECTORS

M Avedissian BL Eghiayan DM Hicks A Sarkissian

SECRETARY

BL Eghiayan

REGISTERED OFFICE

23 Wigmore Street London W1U 1PL

Cambridge Pharmaceuticals Limited DIRECTORS' REPORT

The directors submit their report and the financial statements of Cambridge Pharmaceuticals Limited for the period ended 31 March 2005.

INCORPORATION

The company was incorporated on 5 December 2003 as Foldervocal Limited. On 1 March 2004 the company changed its name to Cambridge Pharmaceuticals Limited.

PRINCIPAL ACTIVITIES

The company was dormant throughout the period.

REVIEW OF THE BUSINESS

DIRECTORS

The following directors have held office since incorporation:

Instant Companies Ltd

(appointed 5 December 2003; resigned 1 March 2004)

M Avedissian

(appointed 23 December 2003)

BL Eghiayan

(appointed 23 December 2003)

(appointed 23 December 2003)

DM Hicks

A Sarkissian

(appointed 23 December 2003)

DIRECTORS' INTERESTS IN SHARES

Directors' interests in the shares of the company, including family interests, were as follows:

Ordinary shares of £I each

Instant Companies Limited

M Avedissian

BL Eghiayan

DM Hicks

A Sarkissyan

31.3.05

This report has been prepared in accordance with the special provisions of Part VII of the Companies Act 1985 relating to small companies.

On behalf of the board

Cambridge Pharmaceuticals Limited DIRECTORS' RESPONSIBILITIES IN THE PREPARATION OF FINANCIAL STATEMENTS

Company law requires the directors to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing those financial statements, the directors are required to:

- a. select suitable accounting policies and then apply them consistently;
- b. make judgements and estimates that are reasonable and prudent;
- c. prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the company and to enable them to ensure that the financial statements comply with the requirements of the Companies Act 1985. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Cambridge Pharmaceuticals Limited

BALANCE SHEET 31 March 2005

	Notes	2005 £
CURRENT ASSETS Debtors	3	100
TOTAL ASSETS LESS CURRENT LIABILITIES		100
CAPITAL AND RESERVES Called up share capital	4	100
SHAREHOLDERS' FUNDS		100

For the period ended 31 March 2005 the company was entitled to exemption under section 249AA(1) of the Companies Act 1985.

No notice has been deposited with the company under s249B(2) of that Act requiring an audit to be carried out.

The directors acknowledge their responsibility for:

- Ensuring that the company keeps accounting records in accordance with s221, Companies Act 1985;
 and
- b. Preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of its financial year, and of its result for the year then ended in accordance with the requirements of s226, Companies Act 1985, and which otherwise comply with the requirements of the Act so far as they are applicable to the company.

Approved by the board on 1 Aukust 2005

Director

Cambridge Pharmaceuticals Limited NOTES TO THE FINANCIAL STATEMENTS

for the period ended 31 March 2005

1	BASIS OF ACCOUNTING	
	The accounts have been prepared under the historical cost convention.	
2	DEBTORS	2005 £
	Due within one year Other debtors	100
3	SHARE CAPITAL	2005 £
	Authorised: 100 ordinary shares of £1 each	100
	Allotted, issued and fully paid: 100 ordinary shares of £1 each	100
4	RECONCILIATION OF MOVEMENT IN SHAREHOLDERS' FUNDS	2005 £
	Loss for the financial period Proceeds from issue of shares	100
	Net addition to shareholders' funds Opening shareholders' funds	100
	Closing shareholders' funds	100